CROs offering Computational & In-Silico Drug Discovery with Oligonucleotide
11 published
11 published CROs match Computational & In-Silico Drug Discovery and Oligonucleotide.
Locations in this set include United States, China, United Kingdom, India, Japan, and South Korea.
Capabilities that show up most often in this set: Discovery Research, Medicinal Chemistry, High-Throughput Screening, In Vitro Pharmacology, and Preclinical In Vitro Studies.
Matching companies
Alloy TherapeuticsProduct development organization offering AI/ML-driven antibody and multispecific discovery, TCR mimic (TCRm) discovery, and antisense oligonucleotide design, backed by transgenic mouse platforms and pharmacology studies.
Aragen Life SciencesGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
Axcelead Drug Discovery Partners, Inc.Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
ChemDivChemDiv is a fully integrated target-to-clinic CRO headquartered in San Diego, CA, offering drug discovery services including medicinal chemistry, CADD, ADME/DMPK, toxicology, and custom synthesis alongside the industry's largest commercial screening library of 1.6M compounds.
ChemPartnerGlobal preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
HitGen Inc.HitGen Inc. provides drug discovery services built on DNA-encoded library (DEL), fragment-based (FBDD/SBDD) and computational platforms for pharmaceutical and biotech clients. The company also offers oligonucleotide CDMO services and reports serving more than 600 clients globally.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Taros Chemicals GmbH & Co. KGIndependent chemistry CRO in Dortmund, Germany offering discovery chemistry, custom synthesis, medicinal chemistry, and process development for pharma, biotech, and chemical companies since 1999.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/computational-drug-discovery/oligonucleotide.md